ArticleInternational journal of hematologic oncology2019

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response.

Sophy Denker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.